Western Blotting Market - Trends Forecast Till 2028

Market Overview

The global western blotting market is projected to reach USD 1.4 billion by 2026 from USD 1.0 billion in 2021, at a CAGR of 6.7% during the forecast period.

Western blotting is an important technique used in cell and molecular biology. By using a western blot, researchers are able to identify specific proteins from a complex mixture of proteins extracted from cells. Various steps in western blotting include, tissue preparation, gel electrophoresis, transfer of proteins onto membrane, blocking to prevent membrane and antibody interactions, incubation of membrane, and antibody-based detection of proteins.

Increasing government funding in the field of biomedical research, technological development, increasing demand for personalized medicines and rising prevalence of HIV are some of the factors that have supported long-term expansion for Western Blotting Market.

The COVID-19 outbreak has boosted research activity due to efforts to understand the dynamics of the infection. Because of the pandemic, companies have scaled up their operations for testing and tracking the infection. This provides a chance for growth in profits for companies operating in the NGS and PCR markets. The shift in demand for COVID-19, neurobiology, and oncology research has created a huge scope for testing solutions, such as western blotting, flow cytometry, ELISA, and drugs for researchers and laboratories.

Regional Analysis

The Asia Pacific, Latin America, and the Middle East & Africa are expected to offer potential growth opportunities to market players in the coming years due to the diversified healthcare markets in these regions and increasing R&D initiatives to develop innovative proteomic and genomic techniques along with the development of personalized medicine.

Insights are provided for each region and major countries within the regions

Competitive Landscape

Key Players

• Bio-Rad Laboratories, Inc.
• Thermo Fisher Scientific
• Danaher Corporation
• Bio-Techne Corporation
• and Merck KGaA

Recent Developments

• In September 2021, PerkinElmer, Inc. (US) acquired BioLegend (US), a leading provider of life science antibodies and reagents, including primary antibodies and western blot secondary reagents. This acquisition enhances the company’s existing western blotting product portfolio.
• In August 2021, Abcam Plc (UK) acquired BioVision Inc. (US), a global supplier of life science research tools for research, diagnostics, and drug discovery. The company is a leading provider of biochemical and cell-based assays and produces a wide portfolio of other products, including recombinant proteins, antibodies, enzymes, and biochemical compounds for immunoassay technologies such as western blotting.

Reasons to Acquire

• Increase your understanding of the market for identifying the best and suitable strategies and decisions on the basis of sales or revenue fluctuations in terms of volume and value, distribution chain analysis, market trends and factors
• Gain authentic and granular data access for Western Blotting Market so as to understand the trends and the factors involved behind changing market situations
• Qualitative and quantitative data utilization to discover arrays of future growth from the market trends of leaders to market visionaries and then recognize the significant areas to compete in the future
• In-depth analysis of the changing trends of the market by visualizing the historic and forecast year growth patterns

Report Scope